Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 28, 2019 07:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma CFO Adam Pascale Announces Retirement

OCALA, Fla., June 28, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) announced today that Adam Pascale is retiring from the position of Chief Financial Officer after nearly...
June 17, 2019 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Issues Clinical Update for Ampligen Immuno-oncology Program

OCALA, Fla., June 17, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc. (NYSE American: HEB) issued its quarterly update on the progress of its ongoing clinical trials evaluating Ampligen’s ability...
June 12, 2019 15:31 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces First Patient Treated in Phase 2 Ovarian Cancer Clinical Trial Evaluating Ampligen in Combination with Pembrolizumab and Cisplatin

OCALA, Fla., June 12, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma Inc. announced today that the first patient has been treated in the Phase 2 recurrent ovarian cancer...
May 31, 2019 10:16 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Stockholders Approve Reverse Stock Split

OCALA, Fla., May 31, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple...
May 16, 2019 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Reports 2019 First Quarter Financial Results

OCALA Fla., May 16, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types...
May 13, 2019 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Announces Progress Toward Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center

OCALA, Fla., May 13, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple...
May 08, 2019 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma's CEO to Attend BioFlorida Inc.’s 2019 Celebration of Biotechnology

OCALA, Fla., May 08, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma Inc.’s CEO Thomas K. Equels will be attending the 2019 Celebration of Biotechnology where he’ll meet with...
May 06, 2019 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Links Stanford’s ME/CFS Diagnostic to a Potential Path Forward for Ampligen Commercialization

OCALA, Fla., May 06, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple...
April 30, 2019 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Significant Progress in its Ampligen Ovarian Cancer Program

OCALA, Fla., April 30, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple...
April 25, 2019 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma's CEO to Present at Planet MicroCap Showcase 2019

OCALA, Fla., April 25, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers,...